BioSpace News Archive

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, November 1, 2019 to discuss its third quarter operating results

Oxford-based start-up Ultromics has announced the appointment of Amir Hasan as Chief Commercial Officer

Foamix Pharmaceuticals Ltd., a specialty pharmaceutical company, announced that the U.S. Food and Drug Administration has approved its novel AMZEEQTM topical foam, 4%.

Select Medical Corporation, commented on the settlement of a qui tam lawsuit filed in the United States District Court for the Southern District of Indiana against it, certain of its subsidiaries and an Evansville physician by three former employees of Select Specialty Hospital – Evansville, LLC SSH Evansville is a joint venture that operates a critical illness recovery hospital in Evansville, Indiana.

Cytovance® Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced the company will participate in the upcoming Recent Advances in Fermentation Technology Conference to be held October 29 - November 1, 2017 at the Hyatt Coconut Point, Bonita Springs, Florida.

The U.S. Food and Drug Administration is alerting consumers of a voluntary recall by Johnson & Johnson of Johnson’s Baby Powder after FDA testing has found that a sample from one lot of the product contains chrysotile fibers, a type of asbestos.

IRRAS announced that it will be participating at the 69th Congress of Neurological Surgeons’ Annual Meeting CNS 2019 is being held at the Moscone Center, West Building, in San Francisco, CA on October 19-23, 2019.

NGM Biopharmaceuticals, Inc. announced that it will present at two upcoming conferences focused on drug research and development for non-alcoholic steatohepatitis NGM’s lead clinical candidate, aldafermin, is currently in Phase 2b clinical development for the treatment of NASH.

At 26 weeks, 54% of adults and 71% of children treated with ULTOMIRIS demonstrated Complete Thrombotic Microangiopathy (TMA) Response

Additional prescription and over-the-counter ranitidine drugs, including Zantac, are being recalled by Sanofi Consumer Health Inc., Sivem Pharmaceuticals ULC and Teva Canada Limited because they may contain the impurity N-nitrosodimethylamine above acceptable levels.